INVO Fertility Inc Rises on Family Beginnings Acquisition
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 02 Dec 25
INVO Fertility Inc is up 25.44% in pre-market trading, crossing above the 5-day SMA. The company announced its acquisition of Family Beginnings clinic, enhancing its market presence in the Midwest. This strategic move aims to expand its network of fertility centers and integrate innovative INVOcell technology, which is expected to improve patient care and attract more clients. The acquisition reflects INVO's commitment to meeting rising patient demand and enhancing service offerings.
Analyst Views on IVF
About IVF
INVO Fertility Inc., formerly NAYA Biosciences, Inc., is a healthcare services company focused on the fertility marketplace and expanding access to assisted reproductive technology (ART) care for patients in need. Its segments include Fertility Clinic Services, INVOcell Device, and Therapeutics. It focuses on operating fertility clinics, including INVO Centers dedicated primarily to offering the intravaginal culture (IVC) procedure enabled by its INVOcell medical device (INVOcell) and United States-based, in vitro fertilization (IVF) clinics. It has two operational INVO Centers in the United States and one IVF clinic. It is also engaged in the sale and distribution of its INVOcell technology solution to third party-owned and operated fertility clinics. The INVOcell is a proprietary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a natural, intimate, and affordable experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
